Viventia Biotech generates novel human anti-cancer antibody, VB1-050, and identifies its novel target
VB1-050, an IgG MAb, was generated from pooled lymphocytes of cancer patient samples, using Viventia's Hybridomics(TM) platform. This antibody demonstrates preferential binding to a host of tumor cell lines, including breast, liver, prostate and colon, with limited normal tissue reactivity. Further, internalization of VB1-050 was confirmed by the disappearance of membrane bound VB1-050 and its appearance inside the cell. Viventia Biotech retains full global product rights to VB1-050 and has filed patents on both the antibody and the novel Glut-8 target. The Company is seeking partners capable of complementing Viventia's development expertise with their global sales, marketing and commercial capabilities.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.